Integrated scFv identification and CAR T cell generation for AML targeting in vivo
Müller-Tidow, C.; Liu, Y.; Lauk, A.; Sedloev, D.; Brysting, J.; Cetin, E.; Liu, C.; Moennig, M.; Luft, T.; Yun, H.; Schmitt, M.; Sauer, T.; Zhou, F.; Rohde, C.
Show abstract
Cancer immunotherapy has witnessed remarkable advancements, especially in the development of chimeric antigen receptor (CAR) T cell therapy. Here, we integrated single-chain variable fragment (scFv) development with CAR T cell generation based on a newly developed scFv phagemid library. High-throughput long-read PacBio sequencing identified 4.5 x 107 unique full-length scFv proteins within the generated library. In a proof of principle, we screened for scFvs targeting C-type lectin-like molecule-1 (CLL1) with subsequent cloning into a third generation retroviral CAR backbone. Functional assays revealed the specificity and potency of these CAR T cells in targeting CLL1-positive AML cells in vitro. In vivo studies reduced tumor burden and improved survival rates compared to controls. Taken together, screening for tumor specific scFvs against CLL1 can rapidly generate AML specific CAR T cells with effective tumor killing in vivo.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A functional screening platform for engineering chimeric antigen receptors with reduced on-target, off-tumour activation 95%
- Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency 95%
- Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma. 94%
Similar papers in this journal
- BCR, not TCR, repertoire diversity is associated with favorable COVID-19 prognosis 95%
- Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: Insights from in vitro assays 95%
- A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD 94%
Similar papers in this journal
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 94%
- Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy 94%
- A Spatiotemporal Map of Co-Receptor Signaling Networks Underlying B Cell Activation 93%
Similar papers in this journal
- Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells 96%
- Development of a human glioblastoma model using humanized DRAG mice for immunotherapy 92%
- Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule 91%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.